We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Jazz (JAZZ) Q4 Earnings
Read MoreHide Full Article
Wall Street analysts forecast that Jazz Pharmaceuticals (JAZZ - Free Report) will report quarterly earnings of $6.62 per share in its upcoming release, pointing to a year-over-year increase of 0.3%. It is anticipated that revenues will amount to $1.18 billion, exhibiting an increase of 8.4% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 13% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Jazz metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Total revenues- Oncology- Vyxeos' should arrive at $47.69 million. The estimate indicates a change of -10.4% from the prior-year quarter.
It is projected by analysts that the 'Total revenues- Oncology- Defitelio/defibrotide' will reach $56.26 million. The estimate indicates a year-over-year change of -2.4%.
Analysts forecast 'Total revenues- Neuroscience- Oxybate- Xywav' to reach $448.99 million. The estimate points to a change of +12% from the year-ago quarter.
Analysts' assessment points toward 'Total revenues- Neuroscience- Epidiolex/Epidyolex' reaching $297.23 million. The estimate indicates a year-over-year change of +8.1%.
The consensus estimate for 'Total revenues- Neuroscience- Sativex' stands at $5.12 million. The estimate points to a change of -1.1% from the year-ago quarter.
The combined assessment of analysts suggests that 'Total revenues- Neuroscience- Oxybate (Xywav & Xyrem)' will likely reach $481.03 million. The estimate points to a change of +6.8% from the year-ago quarter.
The consensus among analysts is that 'Total revenues- Neuroscience- Total' will reach $783.39 million. The estimate indicates a year-over-year change of +7.2%.
The average prediction of analysts places 'Total revenues- Oncology- Total' at $322.89 million. The estimate points to a change of +10.7% from the year-ago quarter.
According to the collective judgment of analysts, 'Total revenues- Oncology- Rylaze/Enrylaze' should come in at $105.81 million. The estimate suggests a change of +4.3% year over year.
The collective assessment of analysts points to an estimated 'Total revenues- Oncology- Zepzelca' of $84.24 million. The estimate indicates a change of +7.6% from the prior-year quarter.
Analysts expect 'Revenues- Product sales, net' to come in at $1.11 billion. The estimate points to a change of +8.2% from the year-ago quarter.
Analysts predict that the 'Revenues- Royalties and contract revenues' will reach $63.75 million. The estimate points to a change of +1.3% from the year-ago quarter.
Over the past month, Jazz shares have recorded returns of -0.3% versus the Zacks S&P 500 composite's -0.8% change. Based on its Zacks Rank #3 (Hold), JAZZ will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Jazz (JAZZ) Q4 Earnings
Wall Street analysts forecast that Jazz Pharmaceuticals (JAZZ - Free Report) will report quarterly earnings of $6.62 per share in its upcoming release, pointing to a year-over-year increase of 0.3%. It is anticipated that revenues will amount to $1.18 billion, exhibiting an increase of 8.4% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 13% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Jazz metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Total revenues- Oncology- Vyxeos' should arrive at $47.69 million. The estimate indicates a change of -10.4% from the prior-year quarter.
It is projected by analysts that the 'Total revenues- Oncology- Defitelio/defibrotide' will reach $56.26 million. The estimate indicates a year-over-year change of -2.4%.
Analysts forecast 'Total revenues- Neuroscience- Oxybate- Xywav' to reach $448.99 million. The estimate points to a change of +12% from the year-ago quarter.
Analysts' assessment points toward 'Total revenues- Neuroscience- Epidiolex/Epidyolex' reaching $297.23 million. The estimate indicates a year-over-year change of +8.1%.
The consensus estimate for 'Total revenues- Neuroscience- Sativex' stands at $5.12 million. The estimate points to a change of -1.1% from the year-ago quarter.
The combined assessment of analysts suggests that 'Total revenues- Neuroscience- Oxybate (Xywav & Xyrem)' will likely reach $481.03 million. The estimate points to a change of +6.8% from the year-ago quarter.
The consensus among analysts is that 'Total revenues- Neuroscience- Total' will reach $783.39 million. The estimate indicates a year-over-year change of +7.2%.
The average prediction of analysts places 'Total revenues- Oncology- Total' at $322.89 million. The estimate points to a change of +10.7% from the year-ago quarter.
According to the collective judgment of analysts, 'Total revenues- Oncology- Rylaze/Enrylaze' should come in at $105.81 million. The estimate suggests a change of +4.3% year over year.
The collective assessment of analysts points to an estimated 'Total revenues- Oncology- Zepzelca' of $84.24 million. The estimate indicates a change of +7.6% from the prior-year quarter.
Analysts expect 'Revenues- Product sales, net' to come in at $1.11 billion. The estimate points to a change of +8.2% from the year-ago quarter.
Analysts predict that the 'Revenues- Royalties and contract revenues' will reach $63.75 million. The estimate points to a change of +1.3% from the year-ago quarter.
View all Key Company Metrics for Jazz here>>>Over the past month, Jazz shares have recorded returns of -0.3% versus the Zacks S&P 500 composite's -0.8% change. Based on its Zacks Rank #3 (Hold), JAZZ will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .